Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic target for managing metabolic syndromes. These naturally occurring molecules are secreted by the gut in response to food intake, stimulating insulin production and suppressing glucagon release. GLP-1 agents possess